Designing and developing a next-gen conjugate, bispecific or fusion protein program? Connect with our experts at PEGs Europe in Lisbon this November 17-19 to de-risk and streamline your drug development strategy.

Our team, including our VP of ADCs and Bioconjugates, Dr. Nicolas Camper, Sr. Director of R&D Business Development, Dr. Ji-won Choi, and Director of R&D Business Development, Dr. Lawrence Welch, will be on hand, exhibiting in booth #303 and presenting on our integrated approach that accelerates the development path for complex biologics, ADCs, AOCs, and more to IND and beyond.

On Wednesday, Nov 18, Nicolas will be speaking on the “Engineering Next-Gen Conjugates Track” at 10am. His talk, titled “Leveraging Conjugation Expertise to Build Efficient CMC Processes in the Development of Antibody-Oligonucleotide Conjugates (AOCs),“ will walk through how Abzena is applying its extensive conjugation experience across 3,000+ molecules to design and develop next-generation AOCs with more controlled oligo loading and improved stability. Through real-world case studies, we’ll demonstrate how AOC programs come together from mAb intermediate development through GMP manufacture and highlight the key decisions that help de-risk development and shorten the path to the clinic.

Schedule some time to meet with our experts at the event to discuss your program: